News

From the previous century onwards, the medical world has been well aware of the power of synergy, which is achieved by combining medicines; in most cases one medicine is less effective than a fixed-dose combination. This is particularly important when treating chronic diseases, e.g. cardiovascular diseases, which have been the leading cause of mortality and morbidity for decades.

The symposium was attended by approx. 230 top cardiologists from 20 countries.

As part of the congress of the European Society of Cardiology held on 26 August in Barcelona, we organised an international Krka symposium entitled The Power of Synergy that was attended by approximately 230 experts from 20 countries. The participants discussed the challenges and advantages of concomitant treatment of high blood pressure and cholesterol, and ways to motivate patients to regularly take their prescribed medicines.

Around 230 top doctors and key opinion leaders were greeted by Krka's Medical Director Breda Barbič-Žagar, who pointed out that Krka is constantly looking for ways to deal with new treatment challenges. Our newest solution is a fixed-dose combination of medicines that enables concomitant treatment of high blood pressure and cholesterol with just one tablet a day. An example of this is a fixed-dose combination of rosuvastatin and amlodipine. Soon we will be the first company in Europe to launch a fixed-dose combination of rosuvastatin and valsartan. These medicines help improve patient compliance, which in turn prevents many cardiovascular events.

The lecturers presented new possibilities in cardiovascular treatment. The professional part of the symposium was moderated by the renowned cardiologist Prof. Krzysztof Narkiewicz from Poland, who presented the possibilities and the significance of concomitant treatment of elevated blood pressure and cholesterol.  He also pointed out the importance of taking the medicines regularly in order to improve treatment outcome. Prof. Zlatko Fras from Slovenia presented the challenges of concomitant treatment of elevated blood pressure and cholesterol, and the advantages of fixed-dose combinations. He said that they additionally reduce the risk of developing cardiovascular diseases and significantly improve patient compliance. Prof. Brian A. Ference from the USA used clinical study results to stress the importance of keeping blood pressure and cholesterol levels low, which in turn significantly reduces cardiovascular risk.

The symposium ended with a lively discussion in which the participants exchanged their experiences and provided answers to the current issues in concomitant treatment of elevated blood pressure and cholesterol.